Treatment of Concurrent Thrombotic Thrombocytopenic Purpura and Graves’ Disease: A Report on Two Cases

  • Lhotta K
  • Zitt E
  • Sprenger-Mähr H
  • et al.
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Graves’ disease (GD) and thrombotic thrombocytopenic purpura (TTP) are autoimmune diseases caused by autoantibodies against the TSH receptor (TRAb) and the enzyme ADAMTS13. We here report on two patients with concurrent GD and TTP, who achieved sustained remission of both conditions with the TTP treatment regimen and thiamazole. Both patients suffered from relapsing TTP and were diagnosed with GD concomitantly at the time of relapse. They were treated with steroids, plasma exchange, rituximab, and thiamazole. This therapy induced complete remission of TTP. TRAb levels also decreased rapidly and both patients developed subclinical hypothyroidism three and five weeks later. Our observations suggest that TTP and GD may be concomitant and that GD possibly triggers a relapse of TTP. The combination of thyrostatic treatment and immunosuppression with PE, rituximab, and steroids is able to induce rapid and prolonged remission of GD.

Cite

CITATION STYLE

APA

Lhotta, K., Zitt, E., Sprenger-Mähr, H., Loacker, L., & Becherer, A. (2018). Treatment of Concurrent Thrombotic Thrombocytopenic Purpura and Graves’ Disease: A Report on Two Cases. Case Reports in Endocrinology, 2018, 1–4. https://doi.org/10.1155/2018/5747969

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free